<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016870</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00050238</org_study_id>
    <nct_id>NCT04016870</nct_id>
  </id_info>
  <brief_title>Project My Heart Your Heart: Pacemaker Reuse</brief_title>
  <acronym>MHYH</acronym>
  <official_title>Project My Heart Your Heart: Prospective Evaluation of the Safety and Efficacy of Cardiac Pacemaker Reuse in Low to Middle Income Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lack of access to pacemakers is a major challenge to the provision of cardiovascular health
      care in Low and Middle Income Countries (LMIC). Post-mortem pacemaker utilization could be
      safe, efficacious, and ethically responsible means of delivering the needed care.
      Reconditioned pacemakers can provide therapy for patients with symptomatic bradycardia and no
      means of receiving a new device. The objective of the clinical trial is to determine if
      pacemaker reutilization can be shown to be a safe means of delivering pacemakers to patients
      in LMIC without resources. Consented patients in this multi-center trial will be randomized
      to undergo implantation of either a reconditioned device or a new device.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 13, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be a randomized, multi-center, single-blinded non-inferiority study of 260 patients (all outside of United States) with Class I indications for pacemaker implantation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Procedure-Related Infection at 12 months</measure>
    <time_frame>12 months post device implantation</time_frame>
    <description>Clinical evidence of pacemaker infection includes local signs of inflammation at the generator site such as erythema, warmth, fluctuance, tenderness, purulent drainage, wound dehiscence, or erosion. Device related endocarditis will be reported if the Duke criteria for infective endocarditis are met. Procedure-related infections will be classified as follows: pocket infection, endocarditis, recurrent bacteremia, extrusion of wires or generator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from Pacemaker Software or Hardware Malfunction at 12 months</measure>
    <time_frame>12 months post device implantation</time_frame>
    <description>Pacemaker software or hardware malfunction include unexpected premature battery depletion, device or electrode malfunction, or unexplained patient death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Device Related Infection</condition>
  <condition>Device Malfunction</condition>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>New Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>New pacemakers will be sourced from pacemaker manufacturers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reconditioned Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reconditioned Pacemaker</intervention_name>
    <description>Devices from the three manufacturers below will be used.</description>
    <arm_group_label>Reconditioned Device</arm_group_label>
    <other_name>St. Jude Medical device</other_name>
    <other_name>Boston Scientific device</other_name>
    <other_name>Medtronic device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New Pacemaker</intervention_name>
    <description>Devices from the four manufacturers below will be used.</description>
    <arm_group_label>New Device</arm_group_label>
    <other_name>St. Jude Medical device</other_name>
    <other_name>Boston Scientific device</other_name>
    <other_name>Medtronic device</other_name>
    <other_name>Biotronik device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life expectancy â‰¥ 2 years.

          -  Indications for device implantation must be fulfilled per standard of care. Consistent
             with 2008 American College of Cardiology / American Heart Association guidelines for
             device therapy, one of the following class I indications must be met.

          -  Sinus Node Dysfunction

          -  Acquired Atrioventricular (AV) Block

          -  Chronic Bifascicular Block

          -  Hypersensitive Carotid Syndrome

          -  Lack of financial ability to pay for a new device must be assessed and documented.

          -  All other methods of new device acquisition must be exhausted.

          -  Patient must be agreeable and able to follow-up with the implanting center within 2
             weeks for wound check, at 2 months, 6 months, and every 6 months thereafter for
             routine pacemaker checks.

        Exclusion Criteria:

          -  Severe valvular disease

          -  Severe pulmonary disease

          -  End-stage renal disease (creatinine clearance &lt; 30 mL/min) whether or not on dialysis

          -  Evidence of ongoing systemic infection

          -  Prior pacemaker or implantable cardioverter-defibrillator implantation

          -  Significant contraindication to pacemaker implantation per evaluation of the
             implanting physician (very high risk of complications).

          -  Presence of any other condition that the local investigator feels would be problematic
             or would restrict or limit the participation of the patient for the entire study
             period

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Crawford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Choithram Memorial Hospital</name>
      <address>
        <city>Freetown</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sierra Leone</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Thomas Crawford</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prosthesis-Related Infections</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

